Molecular signature of Tg B-cell lymphoma
. | . | . | DLCL . | . | . | . | . | . | . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Gene . | SPOR . | RAS . | GC . | AB . | FL . | AT . | TC . | RPB . | CLL . | |
| Bcl2 | +1.6 | +2.7 | - | + | + | - | - | o | + | |
| Bcl6 | -4.4 | -13.4 | + | - | + | o | - | - | - | |
| Casp1 | +5.0 | +3.2 | - | o | o | - | - | o | o | |
| Ccna1 | +2.9 | +1.6 | + | - | o | o | ++ | -- | -- | |
| Ccnb1 | +2.4 | +2.4 | o | - | - | - | + | o | -- | |
| Ccne2 | +3.1 | +8.7 | o | o | o | o | o | o | - | |
| Cd3d | -30.1 | -2.6 | - | - | + | ++ | + | o | - | |
| Cd3e | -40.8 | -2.6 | - | - | + | ++ | + | o | - | |
| Cd38 | +1.6 | +3.2 | + | - | o | o | - | o | - | |
| Cd44 | +10.6 | +5.9 | - | + | - | + | - | o | o | |
| Cdk5 | +1.6 | +2.6 | o | o | o | o | + | o | - | |
| Ches1 | -3.1 | -1.4 | + | - | o | o | o | - | o | |
| Fos | +52.2 | +20.0 | o | o | + | ++ | -- | ++ | -- | |
| Prkcb | +2.4 | +2.0 | o | o | o | - | - | + | ++ | |
| Rara | -6.5 | -18.0 | - | + | o | o | o | o | o | |
| Rb1 | +2.2 | +2.1 | o | o | o | - | o | o | - | |
| Spib | +1.5 | +2.8 | o | o | o | -- | -- | o | - | |
| Tcrb | -5.7 | -3.9 | - | o | + | ++ | o | o | o | |
| Tubb1 | -6.1 | -1.9 | o | o | - | - | + | -- | -- | |
| Vegfa | -9.5 | -6.6 | o | + | o | o | o | o | - | |
. | . | . | DLCL . | . | . | . | . | . | . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Gene . | SPOR . | RAS . | GC . | AB . | FL . | AT . | TC . | RPB . | CLL . | |
| Bcl2 | +1.6 | +2.7 | - | + | + | - | - | o | + | |
| Bcl6 | -4.4 | -13.4 | + | - | + | o | - | - | - | |
| Casp1 | +5.0 | +3.2 | - | o | o | - | - | o | o | |
| Ccna1 | +2.9 | +1.6 | + | - | o | o | ++ | -- | -- | |
| Ccnb1 | +2.4 | +2.4 | o | - | - | - | + | o | -- | |
| Ccne2 | +3.1 | +8.7 | o | o | o | o | o | o | - | |
| Cd3d | -30.1 | -2.6 | - | - | + | ++ | + | o | - | |
| Cd3e | -40.8 | -2.6 | - | - | + | ++ | + | o | - | |
| Cd38 | +1.6 | +3.2 | + | - | o | o | - | o | - | |
| Cd44 | +10.6 | +5.9 | - | + | - | + | - | o | o | |
| Cdk5 | +1.6 | +2.6 | o | o | o | o | + | o | - | |
| Ches1 | -3.1 | -1.4 | + | - | o | o | o | - | o | |
| Fos | +52.2 | +20.0 | o | o | + | ++ | -- | ++ | -- | |
| Prkcb | +2.4 | +2.0 | o | o | o | - | - | + | ++ | |
| Rara | -6.5 | -18.0 | - | + | o | o | o | o | o | |
| Rb1 | +2.2 | +2.1 | o | o | o | - | o | o | - | |
| Spib | +1.5 | +2.8 | o | o | o | -- | -- | o | - | |
| Tcrb | -5.7 | -3.9 | - | o | + | ++ | o | o | o | |
| Tubb1 | -6.1 | -1.9 | o | o | - | - | + | -- | -- | |
| Vegfa | -9.5 | -6.6 | o | + | o | o | o | o | - | |
Most significant changes in gene expression profile of named genes in lymphoma compared with control. About one third of the genome (12000 genes) was significantly expressed. Given the preliminary estimate of variance, about 35% of these were differentially expressed. Comparisons are made to entries in the online databases of Alizadeh et al41 and Shipp et al.42
DLCL indicates diffuse large B-cell lymphoma; SPOR, sporadic Tg B-cell lymphoma; RAS, ras-accelerated Tg B-cell lymphoma; GC, germinal center-like lymphoma41,42 ; AB, activated peripheral B-cell-like lymphoma41,42 ; FL, B-cell follicular lymphoma41,42 ; AT, activated/resting T cell41 ; TC, transformed cell lines41 ; RPB, resting peripheral B cell41 ; CLL, B-cell chronic lymphocytic leukemia41 ; +, small increase; ++, large increase; -, small decrease; --, large decrease; and o, no report, no significant change, or no consistent change within a subclass.
Gene entries (mouse gene abbreviation/human homolog, name): Bcl2/BCL2 indicates B-cell leukemia/lymphoma 2; Bcl6/BCL6, B-cell leukemia/lymphoma 6; Casp1/CASP1, caspase-1; Ccna1/CCNA1, cyclin A1; CCnb1/CCNB1, cyclin B1; Ccne2/CCNE2, cyclin E2; Cd3d/CD3D, CD3 antigen, δ polypeptide; Cd3e/CD3E, CD3 antigen, ϵ polypeptide; Cd38/CD38, CD38 antigen; Cd44/CD44, CD44 antigen; Cdk5/CDK5, cyclin-dependent kinase 5; Ches1/CHES1, checkpoint suppressor 1; Fos/FOS, FBJ osteosarcoma oncogene/v-fos FBJ murine osteosarcoma viral oncogene homolog; Prkcb/PRKCB1, protein kinase Cβ; Rara/RARA, retinoic acid receptor α, Rb1/RB1, retinoblastoma protein; Spib/SPIB, Spi-B transcription factor (Spi-1/PU.1 related); Tcrb/TCRB, T-cell receptor β chain; Tubb1/TUBB1, tubulin β1; Vegfa/VEGF, vascular endothelial growth factor A.
Most significant fold-changes are compared with Shipp et al.42 Figures 5 (DLCL with GC-like vs AB-like signature) and Alizadeh et al.41 Figure 1 (transcriptional profiles of various lymphoid cell types, including GC and AB signatures).